#HVO hVIVO PLC – >£5 million CRS contracts signed November 20, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces its German subsidiary CRS, has signed contracts worth over £5 million since September. The early-phase clinical trial service contracts have been signed with five clients, including two returning mid-sized German pharma customers reaffirming CRS’ strong reputation and long-standing relationships in Germany. These pharma partnerships, given their volume and consistency, strengthens the Group’s sales pipeline…

#HVO hVIVO PLC – Annual Report, Notice of AGM & Directorate Change May 12, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that the Company’s Annual Report and Accounts for the year ended 31 December 2024 and the Notice of Annual General Meeting (“AGM”) will be posted to shareholders today. The 2024 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy are available to download from the Company’s website www.hvivo.com. The Annual…

#HVO hVIVO PLC – Final Results April 10, 2025 – Posted in: Uncategorized

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (“CRO”) and the world leader in human challenge clinical trials, announces its audited results for the year ended 31 December 2024. Financial highlights • Revenue up 11.9% to £62.7 million (2023: £56.0 million) • EBITDA up 25.9% to £16.4 million (2023: £13.0 million) • EBITDA margin of 26.2% (2023: 23.3%) • Underlying EBITDA of £13.4 million (23.0%) excluding the Canary Wharf facility fee and overlapping…

#HVO hVIVO PLC – Notice of Results March 21, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (“CRO”) and the world leader in human challenge clinical trials, announces that it will release its final results for the year ended 31 December 2024 on Thursday 10 April 2025. Analyst briefing A briefing open to equity research analysts will take place on Thursday 10 April 2025 at 11.00am BST. To register and for more details please contact Walbrook PR on hvivo@walbrookpr.com. …

#HVO hVIVO PLC – Director/PDMR Shareholding March 7, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, was notified on 6 March 2025 that 6,440,119 options were exercised by Yamin Khan under the terms of the Company’s Long Term Incentive Plan (“LTIP”) at £0.001 per ordinary share. Of the 6,440,119 options exercised, Mr Khan has sold 3,062,246 ordinary shares of £0.001 each in the Company (“Ordinary Shares”) at 17p per Ordinary Share…

#HVO hVIVO PLC – Acquisition of Cryostore for up to £3.2m February 27, 2025 – Posted in: Blog, hVIVO (HVO), Uncategorized

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (“CRO”) and the world leader in human challenge clinical trials, announces that it has acquired Cryo-Store Limited (“Cryostore” or the “Acquisition”), a specialist provider of high industry standard, temperature-controlled storage solutions for biological and clinical materials. The Acquisition has been completed for consideration of up to £3.2 million, comprising £2.7 million funded from the Group’s existing cash resources and up to £0.5 million in equity…

#HVO hVIVO PLC – hMPV challenge model update January 13, 2025 – Posted in: hVIVO (HVO)

Highlights · hVIVO successfully completes pilot hMPV characterisation study · Study exhibited strong infectivity rate and induced symptomatic disease in healthy volunteers · Now marketing for hMPV challenge trials to support the development of hMPV vaccines and antivirals · Dr Andrew Catchpole to present data from the study at the 13th International RSV Symposium in Brazil hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and…

#HVO hVIVO PLC – COVID-19 study published in Nature Communications December 12, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that an additional peer-reviewed paper from the world’s first COVID-19 characterisation trial has been published in Nature Communications. “SARS-CoV-2 human challenge reveals single-gene blood transcriptional biomarkers that discriminate early and late phases of acute respiratory viral infections”, by Rosenheim, J. et al. is available in Nature Communications,…

#HVO hVIVO PLC – Long Term Incentive Plan/ PDMR Notification October 11, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that the Company has granted Yamin Khan, the Company’s Chief Executive Officer, and certain senior employees, a Long Term Incentive Plan (“LTIP”). The awards are intended to reward, incentivise and retain Mr Khan and certain senior employees to deliver sustainable growth for shareholders. Under the LTIP, Mr Khan has…

#HVO hVIVO PLC – Launch of full suite of hLAB standalone services September 30, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the official launch of the full suite of its hLAB service offering, its highly specialised virology and immunology laboratory services for preclinical and clinical drug development. hLAB is an industry leader in virology and clinical trial support and has been providing laboratory services since 1989. In recent…